Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ921MR)

This product GTTS-WQ921MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ921MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15729MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ10024MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ693MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ6620MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ4999MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ8689MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ5737MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ6909MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENB-0040
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW